top of page
News, Events and Updates
Search
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease
Nov 20, 2023
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of
Oct 25, 2023
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Sep 14, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 2, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 9, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 2, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 25, 2023
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Feb 7, 2023
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 14, 2022
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Dec 1, 2022
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 28, 2022
Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress
Oct 17, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 23, 2022
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Aug 2, 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 31, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD
Oct 13, 2021
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
